VIVUS Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
174,946.00
82,647.00
93,107.00
23,302.00
30,511.00
36,950
Depreciation, Depletion & Amortization
973.00
1,112.00
1,387.00
1,080.00
811.00
8,875
Other Funds
34,709.00
-
-
-
-
20,645
Funds from Operations
122,594.00
49,660.00
39,152.00
46,618.00
5,548.00
7,430
Changes in Working Capital
12,731.00
11,555.00
7,180.00
8,453.00
10,816.00
16,177
Net Operating Cash Flow
135,325.00
38,105.00
46,332.00
38,165.00
16,364.00
23,607
Capital Expenditures
1,795.00
262.00
310.00
211.00
21.00
Purchase/Sale of Investments
86,645.00
19,517.00
67,714.00
39,867.00
24,033.00
Net Investing Cash Flow
90,121.00
15,893.00
67,404.00
40,078.00
24,012.00
Issuance/Reduction of Debt, Net
290,247.00
-
8,998.00
8,738.00
26,077.00
Net Financing Cash Flow
270,103.00
2,124.00
8,851.00
8,699.00
26,039.00
Net Change in Cash
44,657.00
20,088.00
12,221.00
10,612.00
18,391.00
Free Cash Flow
137,120.00
38,367.00
46,642.00
37,954.00
16,385.00
Change in Capital Stock
14,565.00
2,124.00
147.00
39.00
38.00
Other Uses
1,681.00
3,362.00
-
-
-

About VIVUS

View Profile
Address
900 East Hamilton Avenue
Campbell California 95008
United States
Employees -
Website http://www.vivus.com
Updated 07/08/2019
VIVUS, Inc. engages in the development and commercialization of novel therapeutic products. Its products include Qsymia and STENDRA/SPEDRA. The company was founded by Virgil A.